Picture of Ilyang Pharmaceutical Co logo

007570 Ilyang Pharmaceutical Co Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareBalancedSmall CapNeutral

Annual cashflow statement for Ilyang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2020
December 31st
2021
December 31st
2022
December 31st
R2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line21,54525,95631,741-2,03010,508
Depreciation
Non-Cash Items11,90919,73012,16817,8063,270
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital11,3668,684-27,037-13,128-17,987
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities57,48467,02029,93614,6195,615
Capital Expenditures-24,622-21,352-20,535-6,832-40,623
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items3,4628.2428,121-4,6833,448
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities-21,160-21,3447,585-11,516-37,175
Financing Cash Flow Items-142-31,524184-22-0.559
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-30,961-43,127-23,396-6,97832,240
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash5,4466,39011,865-3,759881